twistbioscience.com (TWST) - Debt to Equity

This financing structure chart (debt-to-equity) on GURU.Markets illustrates leverage dynamics, where 0.22 is the current value of the metric. Stability is driven by the deep integration of DNA synthesis into the R&D of pharma behemoths. Diversification into the agricultural sector and data storage minimizes risks. Meanwhile, the proprietary silicon method allows Twist Bioscience (TWST) to aggressively reduce costs, squeezing traditional players out of the market.

A defensive portfolio requires strict leverage control to minimize default risks. This ratio compares total borrowed funds to net asset value, determining the business's degree of dependence on creditors. For Twist Bioscience (TWST), with its expansion into DNA synthesis and high B2B customer loyalty, low debt is critically important. The value of 0.22 confirms the stability of the balance sheet structure. Analyzing the current total liabilities-to-equity ratio, an investor sees organic growth without excessive credit pressure.